Form 4: Charles River Laboratories Executive VP & CFO, Flavia Pease, Reports Acquisition and Disposal of Shares
SEC Form 4 Filing
Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories, reports acquiring shares through restricted stock units and stock options, while also disposing of shares.
Summary
- On May 31, 2024, Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories International, Inc., reported transactions involving the company's stock.
- Pease acquired 2,159 shares of common stock at $0, and disposed of 9,760 shares.
- She also acquired 4,906 stock options with an exercise price of $208.44, exercisable starting May 31, 2025, and expiring on May 31, 2034.
- Following these transactions, Pease beneficially owns 4,906 derivative securities and 9,760 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions. The acquisition of options and stock could be seen as positive, but the disposal of shares tempers this.
Positives
- The acquisition of stock options and restricted stock units indicates confidence in the company's future performance.
Negatives
- The disposal of 9,760 shares could be interpreted negatively, although the reason for disposal is not specified.
Risks
- The vesting schedule of the stock options and restricted stock units could influence the executive's decisions regarding their tenure with the company.
- Market fluctuations could impact the value of the stock options and restricted stock units.
Industry Context
Insider trading activity is closely monitored in the pharmaceutical and biotechnology industries to ensure fair market practices and prevent information asymmetry. This filing provides transparency into the transactions of a key executive at Charles River Laboratories.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The vesting schedules and exercise prices of stock options are typical components of executive compensation packages in the biotech industry, often designed to align executive interests with long-term shareholder value.
- Comparable companies like Laboratory Corporation of America Holdings (LH) and Quest Diagnostics (DGX) also have similar insider transaction reporting requirements.
Stakeholder Impact
- Shareholders may be interested in the insider's transactions as an indicator of management's confidence in the company.
- Employees may view the stock option grants as a positive sign of the company's commitment to employee compensation.
Key Dates
| Date | Description |
|---|---|
| 05/31/2024 | Date of earliest transaction (acquisition and disposal of shares and stock options). |
| 05/31/2025 | First vesting date for 539 restricted stock units and 1,226 stock options. |
| 05/31/2026 | Vesting date for 540 restricted stock units and 1,227 stock options. |
| 05/31/2027 | Vesting date for 540 restricted stock units and 1,226 stock options. |
| 05/31/2028 | Vesting date for 540 restricted stock units and 1,227 stock options. |
| 05/31/2034 | Expiration date for the stock options. |
| 06/03/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.